Severe Rotavirus Gastroenteritis Clinical Trial
— ROSEOfficial title:
Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Assess the Efficacy and Safety of a Pentavalent Rotavirus Vaccine (BRV-PV) Against Severe Rotavirus Gastroenteritis Among Infants in Niger
| NCT number | NCT02145000 |
| Other study ID # | R822388 |
| Secondary ID | |
| Status | Completed |
| Phase | Phase 3 |
| First received | |
| Last updated | |
| Start date | June 2014 |
| Est. completion date | December 31, 2020 |
| Verified date | September 2023 |
| Source | Epicentre |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The study is a double-blinded, randomized, placebo-controlled, trial with two groups of infants receiving vaccine or placebo to assess the efficacy and safety of BRV-PV. Three doses of BRV-PV containing ≥ Log10 5.6 FFU/Dose of each serotype G1, G2, G3, G4 and G9 will be administered at 4 week intervals between doses. The first administration will occur at 6-8 weeks of age. We hypothesize a difference in vaccine efficacy of three doses of BRV-PV vaccine vs. placebo against severe rotavirus gastroenteritis in healthy infants in Niger. Active surveillance for gastroenteritis episodes will be conducted throughout the trial. Surveillance for adverse events will be carried out among all children from the time of first vaccination and 28 days post-Dose 3. Surveillance for all serious adverse events, including intussusception and death, will be conducted on all participants until they each reach two years of age. To assess the effect of prenatal nutrition supplementation on infant immune response to the BRV-PV vaccine, study villages in the immunogenicity sub-cohort will be randomized in a 1:1:1 ratio to provide pregnant women with daily iron-folate, multiple micronutrients or a lipid-based nutrition supplement. Infants of participating women, if eligible at 6-8 weeks of age, will be randomized in a 1:1 ratio to receive three doses of vaccine or placebo and enter the main trial as part of the immunogenicity sub-cohort.
| Status | Completed |
| Enrollment | 6586 |
| Est. completion date | December 31, 2020 |
| Est. primary completion date | December 2015 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 6 Weeks to 2 Years |
| Eligibility | Inclusion Criteria: 1. aged 6-8 weeks at the time of inclusion 2. able to swallow and no history of vomiting within 24 hours 3. resident in Madarounfa Health District and within the catchment area of the central health facility 4. intending to remain in the study area for 2 years 5. parent/guardian providing written informed consent Exclusion Criteria: Any of the following will exclude an infant from randomization in the study: 1. known history of congenital abdominal disorders, intussusception, or abdominal surgery 2. receipt of intramuscular, oral, or intravenous corticosteroid treatment within 2 wks 3. receipt or planned administration of a blood transfusion or blood products, including immunoglobulins 4. any known immunodeficiency condition 5. any serious medical condition 6. any other condition in which, in the judgment of the investigator, would interfere with or serves as a contraindication to protocol adherence or the parent/guardian's ability to give informed consent |
| Country | Name | City | State |
|---|---|---|---|
| Niger | Madarounfa Health District | Madarounfa | Maradi |
| Lead Sponsor | Collaborator |
|---|---|
| Epicentre | Children's Hospital Medical Center, Cincinnati, FORSANI (Forum Santé Niger), Medecins Sans Frontieres, Netherlands, Ministère de la Santé Publique, Niger, Serum Institute of India Pvt. Ltd. |
Niger,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Laboratory-confirmed episode of severe rotavirus gastroenteritis | From 28 days post-Dose 3 until 117 cases are accrued or when all participating infants reach 2 years of age if 117 cases are not attained | ||
| Secondary | Laboratory-confirmed episode of rotavirus gastroenteritis of any severity | From 28 days post-Dose 3 to 1 year of age, from 1 to 2 years of age, and from 28 days post-Dose 3 to 2 years of age | ||
| Secondary | Laboratory-confirmed episode of rotavirus gastroenteritis with a Vesikari score of = 17 | From 28 days post-Dose 3 to 1 year of age, from 1 to 2 years of age, and from 28 days post-Dose 3 to 2 years of age | ||
| Secondary | Laboratory-confirmed episode of severe rotavirus gastroenteritis due to rotavirus serotypes G1, G2, G3, G4 and G9 | From 28 days post-Dose 3 to 1 year of age, from 1 to 2 years of age, and from 28 days post-Dose 3 to 2 years of age | ||
| Secondary | Episode of gastroenteritis of any cause | From 28 days post-Dose 3 to 1 year of age, from 1 to 2 years of age, and from 28 days post-Dose 3 to 2 years of age | ||
| Secondary | Hospitalization due to laboratory-confirmed cases of rotavirus gastroenteritis of any cause | From 28 days post-Dose 3 to 1 year of age, from 1 to 2 years of age, and from 28 days post-Dose 3 to 2 years of age | ||
| Secondary | Hospitalization of any cause | From 28 days post-Dose 3 to 1 year of age, from 1 to 2 years of age, and from 28 days post-Dose 3 to 2 years of age | ||
| Secondary | Any adverse health event | From the time of Dose 1 to 28 days post-Dose 3 | ||
| Secondary | Serious adverse events | From the time of Dose 1 until 2 years of age | ||
| Secondary | Anti-rotavirus IgA sero-response rate | 28 days post-Dose 3 | ||
| Secondary | Anti-rotavirus IgA geometric mean titres | 28 days post-Dose 3 |